Abstract
Most depressed patients suffer from sleep abnormalities, which are one of the critical symptoms of depression. They are robust risk factors for the initiation and development of depression. Studies about sleep electroencephalograms have shown characteristic changes in depression such as reductions in non-rapid eye movement sleep production, disruptions of sleep continuity and disinhibition of rapid eye movement (REM) sleep. REM sleep alterations include a decrease in REM sleep latency, an increase in REM sleep duration and REM sleep density with respect to depressive episodes. Emotional brain processing dependent on the normal sleep-wake regulation seems to be failed in depression, which also promotes the development of clinical depression. Also, REM sleep alterations have been considered as biomarkers of depression. The disturbances of norepinephrine and serotonin systems may contribute to REM sleep abnormalities in depression. Lastly, this review also discusses the effects of different antidepressants on REM sleep disturbances in depression.
Keywords: Antidepressants, depression, mood disorders, norepinephrine, serotonin, sleep disorders.
Graphical Abstract
Current Neuropharmacology
Title:The Neurobiological Mechanisms and Treatments of REM Sleep Disturbances in Depression
Volume: 13 Issue: 4
Author(s): Yi-Qun Wang, Rui Li, Meng-Qi Zhang, Ze Zhang, Wei-Min Qu and Zhi-Li Huang
Affiliation:
Keywords: Antidepressants, depression, mood disorders, norepinephrine, serotonin, sleep disorders.
Abstract: Most depressed patients suffer from sleep abnormalities, which are one of the critical symptoms of depression. They are robust risk factors for the initiation and development of depression. Studies about sleep electroencephalograms have shown characteristic changes in depression such as reductions in non-rapid eye movement sleep production, disruptions of sleep continuity and disinhibition of rapid eye movement (REM) sleep. REM sleep alterations include a decrease in REM sleep latency, an increase in REM sleep duration and REM sleep density with respect to depressive episodes. Emotional brain processing dependent on the normal sleep-wake regulation seems to be failed in depression, which also promotes the development of clinical depression. Also, REM sleep alterations have been considered as biomarkers of depression. The disturbances of norepinephrine and serotonin systems may contribute to REM sleep abnormalities in depression. Lastly, this review also discusses the effects of different antidepressants on REM sleep disturbances in depression.
Export Options
About this article
Cite this article as:
Wang Yi-Qun, Li Rui, Zhang Meng-Qi, Zhang Ze, Qu Wei-Min and Huang Zhi-Li, The Neurobiological Mechanisms and Treatments of REM Sleep Disturbances in Depression, Current Neuropharmacology 2015; 13 (4) . https://dx.doi.org/10.2174/1570159X13666150310002540
DOI https://dx.doi.org/10.2174/1570159X13666150310002540 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Selegiline (l-Deprenyl) as a Unique Neuroprotective Agent for Chronic Neurodegenerative Disorders- A Lesson from MAO Inhibition
Current Medicinal Chemistry - Central Nervous System Agents The Serpin Solution; Targeting Thrombotic and Thrombolytic Serine Proteases in Inflammation
Cardiovascular & Hematological Disorders-Drug Targets Metabolism and Pharmacological Mechanisms of Active Ingredients in <i>Erigeron breviscapus</i>
Current Drug Metabolism The Human Leukocyte Antigen Class III Haplotype Approach: New Insight in Alzheimer's Disease Inflammation Hypothesis
Current Alzheimer Research Amyloid Beta Protein as a Marker or Risk Factor of Alzheimers Disease
Current Alzheimer Research Inhibition of Tau Aggregation in Cell Models of Tauopathy
Current Alzheimer Research Recent Developments on the Studies of Human Memapsin 2 (β-Secretase)
Current Alzheimer Research The Effects of Angiotensin II Signaling Blockade on Platelet Activity in Subjects with Hypertension
Current Hypertension Reviews Oxidative Stress Correlates (OSC) in Diabetes Mellitus Patients
Current Diabetes Reviews Clinical and Environmental Correlates of Serum BDNF: A Descriptive Study with Plausible Implications for AD Research
Current Alzheimer Research Effects of Mindfulness on Diabetes Mellitus: Rationale and Overview
Current Diabetes Reviews Neuronal Ceroid Lipofuscinosis: The Increasing Spectrum of an Old Disease
Current Molecular Medicine The Role of Glucose in the Pathogenesis of Alzheimers Disease Revisited:What Does it Tell us About the Therapeutic use of Lithium?
Central Nervous System Agents in Medicinal Chemistry Glial Reaction in Parkinsons Diseases: Inflammatory Activation Signaling of Glia as a Potential Therapeutic Target
Current Signal Transduction Therapy Complement C4A and C4B Gene Copy Number Study in Alzheimer's Disease Patients
Current Alzheimer Research GABA Receptors: Pharmacological Potential and Pitfalls
Current Pharmaceutical Design BACE1 Deficient Mice: Their Role in Drug Target Validation and Implications for Alzheimers Disease Therapies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Platelet and Soluble Glycoprotein VI - Novel Applications in Diagnosis and Therapy
Current Drug Targets The Challenges of Blood Pressure Control in Dialysis Patients
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Insights on the Neuromodulatory Propensity of Selaginella (Sanjeevani) and its Potential Pharmacological Applications
CNS & Neurological Disorders - Drug Targets